Bristol-Myers Squibb Completes Previously Announced Acquisition of Padlock Therapeutics, Inc.
April 01 2016 - 3:15PM
Business Wire
Bristol-Myers Squibb Company (NYSE: BMY) today announced that it
has completed the previously announced planned acquisition of
Padlock Therapeutics, Inc.
The transaction includes full rights to Padlock’s
Protein/Peptidyl Arginine Deiminase inhibitor discovery program
focused on the development of potentially transformational
treatment approaches for patients with rheumatoid arthritis and
other autoimmune diseases.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, and YouTube.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based
on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Among other risks, there can be no guarantee
that the expected benefits of the acquisition will be
realized. In addition, the compounds described in this release
are subject to all the risks inherent in the drug development
process, and there can be no assurance that the development of
these compounds will be successful. Forward-looking statements in
the press release should be evaluated together with the many
uncertainties that affect Bristol-Myers Squibb's business,
particularly those identified in the cautionary factors discussion
in Bristol-Myers Squibb's Annual Report on Form 10-K for the year
ended December 31, 2015, its Quarterly Reports on Form 10-Q, and
Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or
otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160401005783/en/
Bristol-Myers SquibbMedia:Ken Dominski,
609-252-5251ken.dominski@bms.comorInvestors:Ranya Dajani,
609-252-5330ranya.dajani@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2024 to May 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From May 2023 to May 2024